Hypersensitivity reactions to oxaliplatin: Clinical features and risk factors in Koreans

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1209-1215

  Kim, Mi Yeong ^a   Kang, Sung Yoon ^a   Lee, Suh Young ^a   Yang, Min Suk ^a   Kim, Min Hye ^a   Song, Woo Jung ^a,b   Kim, Sae Hoon ^a,b   Kim, You Jung ^a,b   Lee, Keun Wook ^a,b   Cho, Sang Heon ^a   Min, Kyung Up ^a   Lee, Jong Seok ^a,b   Kim, Jee Hyun ^a,b   Chang, Yoon Seok ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Drug hypersensitivity; Electronic health records; Hypersensitivity; Oxaliplatin

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DEXAMETHASONE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; OXALIPLATIN; PLATINUM COMPLEX;

AGED; ANAPHYLAXIS; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA;

AGED; ANAPHYLAXIS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DEXAMETHASONE; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; FLUOROURACIL; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROCORTISONE; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PREVALENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84873027526     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1209     Document Type: Article

References (34)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51.
2. Bajetta E, Pietrantonio F, Di Bartolomeo M, Buzzoni R (2010). Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori, 96, 154-6.
3. Basu R, Rajkumar A, Datta NR (2002). Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol, 7, 365-7.
4. Bautista MA, Stevens WT, Chen CS, et al (2010). Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol, 3, 12.
5. Bhargava P, Gammon D, McCormick MJ (2004). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 100, 211-2.
6. Brandi G, Pantaleo MA, Galli C, et al (2003). Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer, 89, 477-81.
7. Collet E, Leguy-Seguin V, Jolimoy G, et al (2007). Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immun, 119, 726-30.
8. Faivre S, Chan C, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37.
9. Garufi C, Cristaudo A, Vanni B, et al (2003). Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 14, 497-8.
10. Gowda A, Goel R, Berdzik J, et al (2004). Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology, 18, 1671-5; discussion 6, 80, 83-4.
11. Ichikawa Y, Goto A, Hirokawa S, et al (2009). Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol, 39, 616-20.
12. Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7, 573-84.
13. Kidera Y, Satoh T, Ueda S, et al (2011). High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol, 16, 244-9.
14. Kim BH, Bradley T, Tai J, Budman DR (2009). Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology, 76, 231-8.
15. Koren C, Yerushalmi R, Katz A, et al (2002). Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol, 25, 625-6.
16. Lee KH, Park YJ, Kim ES, et al (2006). Hypersensitivity reactions to oxaliplatin. Cancer Res Treat, 38, 240-1.
17. Lee MY, Yang MH, Liu JH, et al (2007). Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer, 15, 89-93.
18. Lim KH, Huang MJ, Lin HC, et al. (2004). Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs, 15, 605-7.
19. Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005). Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer, 41, 2262-7.
20. Makrilia N, Syrigou E, Kaklamanos I, et al (2010). Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs, ??, ??.
21. Markman M, Kennedy A, Webster K, et al (1999). An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol, 125, 427-9.
22. Mason JM, Rees G (2010). Oxaliplatin-induced acute thrombocytopenia. J Oncol Pharm Pract, 17, 433-5.
23. Morgan JS, Adams M, Mason MD (1994). Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer, 30A, 1205-6.
24. Petit-Laurent F, Conroy T, Krakowski I, et al (2000). [Delayed urticaria with oxaliplatin]. Gastroenterol Clin Biol, 24, 851-2.
25. Polyzos A, Tsavaris N, Gogas H, et al (2009). Clinical features of hypersensitivity reactions to oxaliplatin: a 10- year experience. Oncology, 76, 36-41.
26. Polyzos A, Tsavaris N, Kosmas C, et al (2001). Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology, 61, 129-33.
27. Santini D, Tonini G, Salerno A, et al (2001). Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol, 12, 132-3.
28. Shao YY, Hu FC, Liang JT, et al. (2010). Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc, 109, 362-8.
29. Shibata Y, Ariyama H, Baba E, et al (2009). Oxaliplatininduced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol, 14, 397-401.
30. Siu SW, Chan RT, Au GK (2006). Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol, 17, 259-61.
31. Thomas RR, Quinn MG, Schuler B, Grem JL (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 97, 2301-7.
32. Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81.
33. Villee C, Tennstedt D, Marot L, et al (2010). Delayed urticaria with oxaliplatin. Contact Dermatitis, 63, 50-3.
34. Zanotti KM, Rybicki LA, Kennedy AW, et al (2001). Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol, 19, 3126-9.